(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification[7]: C12N

(21) International Application Number:
PCT/US2003/031519

(22) International Filing Date: 27 October 2003 (27.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/422,389   30 October 2002 (30.10.2002)   US

(71) Applicant (for all designated States except US): THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY [US/US]; 3601 Spruce Street, Philadelphia, PA 19104 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): CATON, Andrew, J. [US/US]; 5 Chestnut Avenue, Narberth, PA 19072 (US).

(74) Agents: BAK, Mary, E. et al.; Howson and Howson, Spring House Corporate Center, P.O. Box 457, Sping House, PA 19477 (US).

(81) Designated States (national): AU, CA, JP, US.

(84) Designated States (regional): European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

Published:
— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MOUSE MODEL FOR AUTOIMMUNE DISORDERS

(57) Abstract: A non-human mammalian model of an autoimmune disorder co-expresses a major histocompatibility (MHC) class II-restricted T cell receptor (TCR) and a selected peptide that binds to the TCR. The selected peptide is selectively expressed by MHC class II positive antigen presenting cells (APC) of the mammal. Models with high penetrance of disease are those in which the selected peptide is a MHC class II-restricted T cell determinant that specifically binds with high affinity to the TCR. Models with low penetrance of disease are those in which the selected peptide binds with low affinity to the TCR. These models, which may be transgenic mammals, are used in method for identifying diagnostic and therapeutic markers and targets characteristic of an autoimmune disorder.